SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-21-004599
Filing Date
2021-11-15
Accepted
2021-11-15 16:13:35
Documents
51
Period of Report
2021-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q labp-20210930.htm   iXBRL 10-Q 1874931
2 EX-31.1 labp-ex31_1.htm EX-31.1 25179
3 EX-31.2 labp-ex31_2.htm EX-31.2 23112
4 EX-32.1 labp-ex32_1.htm EX-32.1 15056
5 EX-32.2 labp-ex32_2.htm EX-32.2 14576
  Complete submission text file 0000950170-21-004599.txt   6069733

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT labp-20210930_def.xml EX-101.DEF 99250
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT labp-20210930.xsd EX-101.SCH 32153
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT labp-20210930_lab.xml EX-101.LAB 335405
9 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT labp-20210930_cal.xml EX-101.CAL 35329
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT labp-20210930_pre.xml EX-101.PRE 224544
11 EXTRACTED XBRL INSTANCE DOCUMENT labp-20210930_htm.xml XML 1048381
Mailing Address 1800 KRAFT DRIVE, SUITE 216 BLACKSBURG VA 24060
Business Address 1800 KRAFT DRIVE, SUITE 216 BLACKSBURG VA 24060 540-818-2844
Landos Biopharma, Inc. (Filer) CIK: 0001785345 (see all company filings)

IRS No.: 815085535 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39971 | Film No.: 211410722
SIC: 2834 Pharmaceutical Preparations